Fresh from a $72M raise, Jeff Aronin's new lead rare disease drug is flagged as a failure
Just a few days after one of Jeff Aronin’s biotechs put out the word that they had raised $71.8 million to push their rare disease drug into pivotal trials, the company quietly flagged the treatment’s failure in Phase II.
But they are going for Phase III anyway.
The clinicaltrials.gov page on the Phase II study of Castle Creek’s only drug was updated on October 22 and now reads that the trial was terminated after an independent data monitoring committee “suggested that the study will not meet statistical objectives.” The page also includes a timeline with a wrap due in the middle of October.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.